Evidence map›Paper›PMID 36553615›Full record

ArticleGenes2022

Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing.

Yujuan Hou, Guillermo Ureña-Bailén, Tahereh Mohammadian Gol, Paul Gerhard Gratz, Hans Peter Gratz, Alicia Roig-Merino, Justin S Antony, Andrés Lamsfus-Calle, Alberto Daniel-Moreno, Rupert Handgretinger and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Prime Editing: An Overview.Methods in molecular biology (Clifton, N.J.) · 2027
    Review
  3. Article
  4. Review
  5. Article
  6. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.International journal of molecular sciences · 2023
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Yujuan HouDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.
Guillermo Ureña-BailénDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.ORCID 0000-0003-4699-7486
Tahereh Mohammadian GolDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.
Paul Gerhard GratzDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.
Hans Peter GratzDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.
Alicia Roig-MerinoMaxCyte Inc., Rockville, MD 20850, USA.ORCID 0000-0003-0775-5820
Justin S AntonyDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.
Andrés Lamsfus-CalleDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.ORCID 0000-0002-4464-0152
Alberto Daniel-MorenoDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.
Rupert HandgretingerDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.
Markus MezgerDepartment of Pediatrics I, Hematology and Oncology, University Children's Hospital, University of Tübingen, 72076 Tuebingen, Germany.ORCID 0000-0002-0211-2343
University Children's Hospital Tübingen · DEMaxCyte (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-linked severe combined immunodeficiency (X-SCID) is a primary immunodeficiency that is caused by mutations in the interleukin-2 receptor gamma

Indexed as

X-Linked Combined Immunodeficiency DiseasesCRISPR-Cas SystemsGene EditingGenetic TherapyHumansMosaicismSevere Combined ImmunodeficiencyCRISPR/Cas9IL2RGprime editingSCIDsomatic mosaicismssODN

Identifiers

PMID36553615
PMCPMC9777626
OpenAlexW4311372955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.